Evotec SENASDAQ: EVO

Halozyme CEO Helen Torley joins to discuss the company's intended acquisition of biotech company Evotech. She speaks with Caroline Hyde on "Bloomberg Technology.

HAMBURG, GERMANY / ACCESSWIRE / November 14, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT) (SDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480 (NASDAQ:EVO) With respect to a media report, Evotec SE ("Company") declares that it has received, without prior contact, a non-binding expression of interest from the listed US biotechnology company Halozyme Therapeutics Inc. regarding a takeover offer addressed to the shareholders of the Company with an offer price of EUR 11.00 per share. The Company will carefully analyze this expression of interest, decide on next steps, and inform the capital market in accordance with the legal requirements.

German drugmaker Evotec is attracting takeover interest from U.S.-based Halozyme Therapeutics , Bloomberg News reported on Thursday.

Evotec SE (NASDAQ:EVO ) Q3 2024 Earnings Conference Call November 6, 2024 8:00 AM ET Company Participants Volker Braun - Head of Investor Relations Christian Wojczewski - Chief Executive Officer Laetitia Rouxel - Chief Financial Officer Cord Dohrmann - Chief Scientific Officer Craig Johnstone - Chief Operating Officer & Site Head Toulouse Conference Call Participants Charles Weston - RBC Capital Markets Michael Ryskin - Bank of America Christian Ehmann - Warburg Research Benjamin Jackson - Jefferies Joseph Hedden - Rx Securities Operator Ladies and gentlemen, welcome to the Evotec SE Quarterly Statement Nine Months 2024 Capital Market Briefing Conference Call. I am Sachin, the Chorus Call Operator.

Guidance for 2024 confirmed with full-year 2024 revenue and adjusted EBITDA targets on track, despite challenging market conditions Robust growth of Just - Evotec Biologics driven by roll out of projects together with Sandoz and progress of discovery partnerships Successful extensions & expansions with BMS and Novo Nordisk; new collaboration with Pfizer to advance cutting-edge therapeutic solutions Priority reset on track to deliver annualised adj. EBITDA improvement of over € 40 m and strategic review initiated HAMBURG, GERMANY / ACCESSWIRE / November 6, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO) today announced its financial results and corporate updates for the third quarter of 2024, highlighting strategic progress across key partnerships and operations.

HAMBURG, GERMANY / ACCESSWIRE / October 30, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO) will announce its financial results for the first nine months of 2024 on Wednesday, 06 November 2024. The Company is going to hold a conference call to discuss 9-months results as well as to provide an overview on the ongoing priority reset and the strategic review process.

Key scientific achievements drive the expansion of the pipeline of molecular glue degraders in fields beyond oncology Evotec receives a US$ 50 m payment from Bristol Myers Squibb; potential programme-based milestone payments contribute to the deal value HAMBURG, GERMANY / ACCESSWIRE / October 23, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO) today announced progress within the Company's strategic partnership with Bristol Myers Squibb relating to building a molecular glue-based pipeline. Key scientific achievements drive the expansion of the pipeline of molecular glue degraders in fields beyond oncology, triggering a programme-based payment of US$ 50 m to Evotec.

Kia celebrates the completion of Hyundai Motor Group's first dedicated EV manufacturing facility Kia Gwangmyeong EVO Plant, located at Kia Autoland Gwangmyeong, to mass-produce Kia EV3 and EV4 models The new facility to have production capacity of 150,000 units per year Previous internal combustion engine (ICE) vehicle plant transformed to facilitate EV production and accelerate delivery of Kia's strategic sustainable manufacturing and mobility goals Cutting-edge manufacturing initiatives include water-based painting as well as automated processes The EVO Plant to set a new era for Kia's move towards electrification, through production of the brand's high quality EV lineup SEOUL, South Korea, Sept. 26, 2024 /PRNewswire/ -- Kia Corporation has today celebrated the opening of Kia Gwangmyeong EVO Plant, Hyundai Motor Group's (the Group) first dedicated EV manufacturing facility.

German drug and development company Evotec has entered into a technology development partnership with Novo Nordisk to support clinical and commercial manufacturing of stem cell-based therapies, the company said on Thursday.